Therefore, we used immunohistochemistry to evaluate the quantity and distribution of CD4+ lymphocytes, CD8+ lymphocytes, CD68+ macrophages, CD163+ macrophages, and M1-macrophages in the tumor center and invasion front in a cohort of 55 OSCC patients. This evidence concerns the gene CD163 and neoplasm.